BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.